Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.

How to buy Amedisys stock | 251.67

Own Amedisys stock in just a few minutes.

Posted

Fact checked

Amedisys, Inc is a medical care facilities business based in the US. Amedisys shares (AMED) are listed on the NASDAQ and all prices are listed in US Dollars. Amedisys employs 21,000 staff and has a trailing 12-month revenue of around USD$2 billion.

How to buy shares in Amedisys

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Amedisys Find the stock by name or ticker symbol: AMED. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Amedisys reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$251.67, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Amedisys, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Amedisys. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Amedisys's share price?

Since the stock market crash in March caused by coronavirus, Amedisys's share price has had significant positive movement.

Its last market close was USD$251.67, which is 22.90% up on its pre-crash value of USD$194.03 and 89.30% up on the lowest point reached during the March crash when the shares fell as low as USD$132.9495.

If you had bought USD$1,000 worth of Amedisys shares at the start of February 2020, those shares would have been worth USD$938.56 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,404.32.

Amedisys share price

Use our graph to track the performance of AMED stocks over time.

Amedisys shares at a glance

Information last updated 2020-10-16.
Latest market closeUSD$251.67
52-week rangeUSD$127.12 - USD$258.62
50-day moving average USD$238.1183
200-day moving average USD$209.6756
Wall St. target priceUSD$256
PE ratio 58.1839
Dividend yield N/A (0%)
Earnings per share (TTM) USD$3.861

Compare trading platforms

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
Tastyworks
$0
Stocks, Options, ETFs, Futures
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Amedisys stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Amedisys price performance over time

Historical closes compared with the close of $251.67 from 2020-10-16

1 week (2020-10-13) -0.21%
1 month (2020-09-18) 7.73%
3 months (2020-07-20) 16.46%
6 months (2020-04-20) 28.65%
1 year (2019-10-18) 86.06%
2 years (2018-10-19) 132.53%
3 years (2017-10-20) 400.64%
5 years (2015-10-20) 520.79%

Is Amedisys under- or over-valued?

Valuing Amedisys stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Amedisys's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Amedisys's P/E ratio

Amedisys's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 58x. In other words, Amedisys shares trade at around 58x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Amedisys's PEG ratio

Amedisys's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.3995. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Amedisys's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Amedisys's EBITDA

Amedisys's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$201.9 million.

The EBITDA is a measure of a Amedisys's overall financial performance and is widely used to measure a its profitability.

Amedisys financials

Revenue TTM USD$2 billion
Operating margin TTM 9.12%
Gross profit TTM USD$805.3 million
Return on assets TTM 7.89%
Return on equity TTM 20.15%
Profit margin 6.5%
Book value $22.219
Market capitalisation USD$8.2 billion

TTM: trailing 12 months

Shorting Amedisys shares

There are currently 394,471 Amedisys shares held short by investors – that's known as Amedisys's "short interest". This figure is 6.3% down from 420,897 last month.

There are a few different ways that this level of interest in shorting Amedisys shares can be evaluated.

Amedisys's "short interest ratio" (SIR)

Amedisys's "short interest ratio" (SIR) is the quantity of Amedisys shares currently shorted divided by the average quantity of Amedisys shares traded daily (recently around 210947.05882353). Amedisys's SIR currently stands at 1.87. In other words for every 100,000 Amedisys shares traded daily on the market, roughly 1870 shares are currently held short.

However Amedisys's short interest can also be evaluated against the total number of Amedisys shares, or, against the total number of tradable Amedisys shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Amedisys's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Amedisys shares in existence, roughly 10 shares are currently held short) or 0.0142% of the tradable shares (for every 100,000 tradable Amedisys shares, roughly 14 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Amedisys.

Find out more about how you can short Amedisys stock.

Amedisys share dividends

We're not expecting Amedisys to pay a dividend over the next 12 months.

Have Amedisys's shares ever split?

Amedisys's shares were split on a 4:3 basis on 5 December 2006. So if you had owned 3 shares the day before before the split, the next day you'd have owned 4 shares. This wouldn't directly have changed the overall worth of your Amedisys shares – just the quantity. However, indirectly, the new 25% lower share price could have impacted the market appetite for Amedisys shares which in turn could have impacted Amedisys's share price.

Amedisys share price volatility

Over the last 12 months, Amedisys's shares have ranged in value from as little as $127.12 up to $258.62. A popular way to gauge a stock's volatility is its "beta".

AMED.US volatility(beta: 0.89)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amedisys's is 0.8908. This would suggest that Amedisys's shares are less volatile than average (for this exchange).

Amedisys overview

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including heart disease, pulmonary disease, Alzheimer's, or cancer. The Personal Care segment provides assistance for patients with the activities of daily living. As of February 18, 2020, the company owned and operated 479 care centers in 38 states and the District of Columbia. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana.

Frequently asked questions

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site